Jennifer Doak
Global Communications Director Wound Care
Email: jennifer.doak@molnlycke.com
Phone: +1 678 206 6179
Mölnlycke® Health Care and Transdiagen announce research collaboration to drive innovation in wound care
Today, Mölnlycke Health Care, a world leading MedTech company, specialising in wound care and wound management announce a research collaboration with Transdiagen (TDG), a precision medicine company developing drugs and diagnostics for chronic wound healing and tissue regeneration. The collaboration aims to use TDG’s novel wound gene signatures to further explore Mölnlycke products.
Emma Wright, EVP Chief Medical Officer, Mölnlycke commented, “We are excited by our research collaboration with TDG allowing us to be at the forefront of advanced understanding of chronic wounds. This opens up a wealth of opportunities for future innovation in the under resourced and under prioritised area of wound care.”
James Harding, CEO, Transdiagen added “We are thrilled to be working with Mölnlycke on this R&D programme. This collaboration will allow Mölnlycke access to TDG’s novel models to generate functional insights regarding the mode of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data driven, evidence-based product development for the treatment of complex wounds.”
The collaboration will be initiated shortly.
For more information, please contact:
About Mölnlycke
Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com
About Transdiagen
Transdiagen (TDG) is a precision medicine company developing drugs and diagnostics for chronic wound healing and tissue regeneration. TDG is driven by the molecular understanding and clinical outcome of chronic wounds and to delivering the right treatment, to the right patient, at the right time.
TDG has developed novel Ex Vivo models built on clinically validated mRNA biomarkers linking clinical data and patient outcomes. This is the most advanced disease understanding platform for chronic wounds, and powers the creation of novel diagnostics and drugs. The TDG development models and molecular insights translate laboratory data to clinical outcomes, transforming the development lifecycle of novel interventions directing efficacy, product development, disease, and patient selection. TDG is headquartered in the UK. www.transdiagen.com
Latest news
-
Mölnlycke joins National Climate Initiative within healthcare and life science
A broad public–private partnership is now being launched to accelerate the green transition within the Swedish healthcare and life science sector. The initiative aims, through collaboration, to reduce greenhouse gas emissions with the ambition of reaching net zero across the entire value chain by 2045.
-
Mölnlycke® celebrates 100 million ProcedurePak® trays - advancing operating room efficiency worldwide
Gothenburg, Sweden. 27 January 2026. Mölnlycke Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the production of 100 million ProcedurePak® trays at the company’s production sites in the Czech Republic.
-
Making sustainable healthcare work
Healthcare systems worldwide are under pressure to deliver more with less. Fewer resources, tighter budgets, and growing demands. In this article, published in Clinical Services Journal, Eric De Kesel, Chief Operating Officer & Executive Vice President Sustainability and Dr Emma Wright, Chief Medical Officer at Mölnlycke Health Care, explain how Mölnlycke is turning sustainable healthcare from aspiration into practice by connecting performance, people, and planet.
-
Clinician wellbeing is key to sustainable healthcare
Clinician wellbeing is the cornerstone of sustainable healthcare. Dr Emma Wright, Chief Medical Officer at Mölnlycke Health Care, explains why supporting those who deliver care is essential and how value-based healthcare can unlock better outcomes for patients, healthcare professionals, and healthcare systems.
-
Mölnlycke recognised with EUPD’s ‘ESG Transparency Award
We are delighted to announce that Mölnlycke was recognised with ‘ESG Transparency Award' by EUPD Research. Mölnlycke achieved the highest excellence level with the total score of 95,5%.
-
Shaping wound care policy across Europe
We are proud to play our part in shaping the future of wound care in Europe. Mölnlycke has been elected one of the organisations leading the Wound Care Sector Working Group at MedTech Europe, the industry association representing medical technology across the continent.
-
2025 Future Summit by Mölnlycke Health Care
Smarter incision care and partnerships are key to enhanced clinical practise and improved patient outcomes.
-
Mölnlycke donates patent to spark innovation in sustainable healthcare
Gothenburg, Sweden. 12 November 2025. Mölnlycke Health Care, a global leader in MedTech, is the first company to donate a patent to SKF’s groundbreaking digital platform, The Patent Bay – taking bold action to harness collaboration and accelerate innovation in sustainable healthcare.
-
Mölnlycke establishes first wound care manufacturing site in China
Changshu, China, and Gothenburg, Sweden. 5 November 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke’s growth journey and the beginning of localised manufacturing in one of the world’s fastest-growing MedTech markets.